Aripiprazole versus typicals for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Bhattacharjee, Jayanti ^a   El Sayeh, H G G ^b  

^a Cygnet Hospital at Bierley   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RETRACTED ARTICLE; REVIEW;

EID: 44949138279     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006617.pub2     Document Type: Review

References (127)

1. Carson 2000a {published data only} Anutosh S, Ali MW, Ingenito G, Carson WH. Controlled study of aripiprazole and haloperidol in schizophrenia. European Psychiatry 2002;Suppl 1:103s.
2. Aquino P, CE Adams, T Crow, I Wood. Personal communication. Personal Communication 2006.
3. Carson WH, Ali M, Dunbar G, Ingenito G, Saha AR. A double-blind, placebo-controlled trial of aripiprazole and haloperidol. Schizophrenia Research 2001;1-2:221-2. [MEDLINE: 21083242].
4. Carson WH, Ali M, Saha AR, Dunbar GC, Ingenito G. A double-blind, placebo-controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico. 2000.
5. * Carson WH, Kane JM, Ali M, Dunbar GC, Ingenito G. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Journal of the European College of Neuropsychopharmacology 2000;10(Suppl 3):S309.
6. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets, medical review part 1. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm 2002:1-50.
7. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets, medical review part 3. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm 2002:111-75.
8. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets, medical review part 4. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm Vol. 2002:176-232.
9. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets; medical review part 2. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm 2002:50-110.
10. Kane J, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Schizophrenia Re-search 2000;1:39. [MEDLINE: 69107662].
11. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 2002;9:763-71.
12. Kane JM, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA. 2000.
13. Kane JM, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA. 2002.
14. Kane JM, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. International Journal of Neuropsychopharmacology 2000;Suppl 1:S124.
15. Csernansky 2003 {unpublished data only} * Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets, medical review part 1. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm 2002:1-50.
16. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets, medical review part 2. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm 2002:51-110.
17. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets, medical review part 3. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm 2002:111-75.
18. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets; medical review part 4. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm 2002:176-232.
19. Daniel 2000 {published data only} * Daniel DG, Saha AR, Ingenito G, Carson WH, Dunbar G. Aripiprazole, a novel antipsychotic: overview of a phase II study result. International Journal of Neuropsychopharmacology 2000;Suppl 1:S157.
20. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets, medical review part 1. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm 2002:1-50.
21. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets, medical review part 3. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm 2002:111-75.
22. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets ; medical review part 2. www.fda.gov/cder/foi/nda/2002/21-436_Abilify. htm 2002:50-110.
23. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets; medical review part 4. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm 2002:176-232.
24. Saha AR, Petrie JL, Ali MW. Safety and efficacy profile of aripiprazole, a novel antipsychotic. Schizophrenia Research 1999;1-3:295. [MEDLINE: 98251670].
25. Daniel 2004a {published data only} Daniel DG, Stock EG, Wilber CH, Marcus RN, Carson Jr WH, Manos G, Iwamoto T. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, Usa. 2004.
26. Gismondi R, Daniel D, Stock E, Wilber R, Carson W, Manos G, Iwamoto T. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. Journal of the European College of Neuropsychopharmacology 2004;14(Suppl.3):S261.
27. Kungel M, Daniel D, Stock E, Wilber R, Marcus R, Carson W, Manos G, Iwamoto T. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update"; 2004 Nov 10-13; Florence, Italy. 2004.
28. Modell S, Daniel D, Stock E, Wilber R, Marcus R, Carson W, Manos G, Iwamoto T. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20-24, Paris, France 2004.
29. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomised double-blind,placebo-controlled trial. Journal of Clinical Psychiatry 2007;68(1):111-9. [MEDLINE: 17284138].
30. Yocca F, Daniel D, Stock E, Oren D, Marcus R, Carson W, Manos G, Iwamoto T. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology ; 2004 Dec 12-16, San Juan, Puerto Rico. 2004.
31. Kane 2003 {unpublished data only} Gismondi R, Meltzer H, Kujawa M, Carson W, Stringfellow J, Iwamoto T, Marcus R, Stock E. Aipiprazole versus perphenazine in treatment-resistant schizophrenia. XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress ; 2004 June 20-24, Paris, France 2004.
32. Kane J, Carson Wh, Kujawa M, Stringfellow J, Marcus R, Sanchez R, Iwamoto T, Meltzer H. Aripiprazole in Treatment-Resistant Schizophrenia: a 6-Week Double- Blind Comparison Study Versus Perphenazine. Schizophrenia Research 2004;67(1):155-6.
33. *Kane J, William HCJ, Kujawa MJ, Stringfellow J, Marcus RN, Sanchez R, Meltzer HY. Aripiprazole vs. perphenazine in treatment-resistant schizophrenia. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003.
34. Kane JM, Meltzer HY, Carson WH Jr, McQuade RD, Marcus RN, Sanchez R, Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia : results of a multicenter, randomised, double-blind, comparison study versus perphenazine. Journal of Clinical Psychiatry 2007;68(2):213-23. [MEDLINE: 17335319].
35. McQuade R, Jody D, Kane J, Carson W, Kujawa M, Stringfellow J, Marcus R, Sanchez R, Meltzer HY. Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia. 16th European College of Neuropsychopharmacology Congress ; 2003 Sep 20-24; Prague, Czech Republic. 2003.
36. McQuade R, Jody D, Kane J, Carson W, Kujawa M, Stringfellow J, Marcus R, Sanchez R, Meltzer HY. Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia. Journal of the European College of Neuropsychopharmacology 2003;13(4):S326.
37. Meltzer HY, Kujawa MJ, Carson Jr WH, Stringfellow J, Iwamoto T, Marcus RN, Stock EG. Aripiprazole and perphenazine in severe treatment-resistant schizophrenia. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, Usa. 2004.
38. Modell S, Jody D, Kujawa M, Carson W, Stringfellow J, Iwamoto T, Marcus R, Stock E. Efficacy of aripiprazole and perphenazine in svere schiziphrenia resistant to treatment with atypical antipsychotics. Journal of the European College of Neuropsychopharmacology 2004;14(Suppl.3):S265.
39. Sanchez R, Meltzer HY, Marcus RN, Stringfellow J, Carson WH, Kane JM. Aripiprazole versus Perphenazine in Treatment - Resistant Schizophrenia. Schizophrenia Bulletin 2005;31:502.
40. Kujawa 2002 {published data only} Archibald DG, Manos G, Stock E, Jody D, Tourkodimitris S, Marcus R, Iwamoto T, Yamamoto Y. Effects of Long-Term Aripiprazole Therapy on the Negative Symptoms of Schizophrenia. Schizophrenia Research 2004;67(1):155.
41. Archibald DG, Manos G, Tourkodimitris S, Iwamoto T, Carson WH, Stock E, Marcus R. Reduction in negative symptoms of schizophrenia during long-term therapy with aripiprazole. Schizophrenia Research 2003;60:271. [MEDLINE: 22587231].
42. Crandall D, Pikalov A, Kostic D, Kaplita S, Berman R, McQuade R, Radhakrishnan M. Is sedation needed for effective reduction of acute schizophrenia symptoms ?. 158th Annual Meeting of the American Psychiatric Association ; 2005 May 21-26; Atlanta, Georgia, USA. 2005.
43. Dubitsky GM, Harris R, Laughren T, Hardeman s. Abilify (aripiprazole) tablets ; medical review part 2. www.fda.gov/cder/foi/nda/2002/21-436_Abilify. htm 2002:50-110.
44. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets, medical review part 1. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm 2002:1-50.
45. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets ; medical review part 3. www.fda.gov/cder/foi/nda/2002/21-436_Abilify. htm 2002:111-75.
46. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets ; medical review part 4. www.fda.gov/cder/foi/nda/2002/21-436_Abilify. htm 2002:176-232.
47. Kane JM, Swyzen W, Wu X, McQuade R, Gutierrez-Esteinou R, Van Tran Q, Marcus R. Long-term symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol. 159th Annual Meeting of the American Psychiatric Association ; 2006 May 20-25, Toronto, Canada. 2006.
48. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. International Journal of Neuropsychopharmacology 2003;6(4):325-37. [MEDLINE: 14609439].
49. Kostic D, Manos G, Stock E, Jody D, Archibald D, Tourkodimitris S, Marcus R. Long-term effects of aripirazole on the negative symptoms of schizophrenia. Journal of the European College of Neuropsychopharmacology 2003;13(4):S328.
50. Kostic D, Marcus RN, Stock EG, Carson WH, Tourkodimitris S, Archibald DG. Maintenance of responce in chronic schizophrenia : effects of aripiprazole and haloperidol on affective symptoms. Schizophrenia Bulletin. 2005; Vol. 31:492.
51. *Kujawa M, Saha AR, Ingenito GG, Ali MW, Luo X, Archibald DG, Carson WH. Aripiprazole for long-term maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology 2002;suppl 1:S186.
52. Kujawa MJ, Saha AR, Ingenito GG, Ali MW, Luo X, Archibald DG, William Jr. HC. Aripiprazole for long-term maintenance treatment in schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA. 2002.
53. Manos G, Stock EG, Jody D, Archibald DG, Tourkodimitris S, Marcus RN. Long-term effects of aripiprazole on the negative symptoms of schizophrenia. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA. 2003.
54. Marder SR, Archibald DG, Manos G, Stock EG, Jody DN, Tourkodimitris S, Marcus RN, Iwamoto T, Yamomoto Y, Carson WH. Long-term effects of aripiprazole therapy on the negative symptoms of schizophrenia. XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress ; 2004 June 20-24 , Paris, France 2004.
55. McQuade R, Carson W, Saha A, Ingenito G, Ali M, Archibald D. Aripiprazole for long-term maintenance treatment of schizophrenia. Journal of the European College of Neuropsychopharmacology 2002;12(Supplement 3):S288.
56. McQuade RD, Kujawa M, Saha AR, Ingenito GG, Ali MW, Luo X, Archibald DG, Carson WH. Aripiprazole for long-term maintenance treatment of schizophrenia. Schizophrenia Research 2003;60:295. [MEDLINE: 2003141918].
57. Octavio I, Stock E, Archibald D, Tourkodimitris S, Kujawa M, Marcus R, Carson W, Iwamoto T. Long-term effects of aripiprazole on affective symptoms of schizophrenia. Journal of the European College of Neuropsychopharmacology 2004;14(Suppl.3):S261.
58. Octavio I, Stock EG, Archibald DG, Tourkodimitris S, Kujawa MJ, Marcus R, Carson WH, Iwamoto T. Long-term effects of aripiprazole on affective symptoms of schizophrenia. XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress ; 2004 June 20-24, Paris, France 2004.
59. Saha AR, Carson WH, Mcquade RD, Stock EG, Inada I, Ali MW. Long-term aripiprazole therapy in schizophrenia. XIIth World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002.
60. Stock E, Archibald Dg, Tourkodimitris S, Kujawa M, Marcus R, Carson W, Iwamoto T. Long-Term Effects of Aripiprazole and Haloperidol on Affective Symptoms of Schizophrenia. Schizophrenia Research 2004;67(1):158- 9.
61. Stock EG, Achibald DG, Tourkodimitris S, Kuwaja MJ, Marcus RN, Carson Jr WH. Long-term effects of arpiprazole on affective symptoms of schizophrenia. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA. 2003.
62. McCue 2006 {published data only} *McCue RE, Waheed R, Urcuyo L, Orendain G, Joseph MD, Charles R, Hasan SM. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. British Journal of Psychiatry 2006;189(Nov):433-40. [MEDLINE: 17077434].
63. Oren 2005a, b {published data only} Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, Iwamoto T. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder ; a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology 2006;188(3): 281-92. [MEDLINE: 16953381].
64. Citrome LL, Vester-Blokland E, Archibald D, McQuade R, Kostic D, Pikalov A, Oren D. Benefits of a second dose of intramuscular (im) aripiprazole to control agitation in patients with schizophrenia or bipolar 1 disorder. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada. 2006.
65. Dillenschneider A, Oren D, Marcus R, Kostic D, McQuade R, Iwamoto T, Manos G. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. Journal of the European College of Neuropsychopharmacology 2005;15(Suppl.3):S509.
66. McQuade R, Auby P, Oren D, Marcus R, Kostic D, Iwamoto T, Manos G. Intramuscular aripiprazole in acute schizophrenia : a double-blind, placebo-controlled comparison with IM haloperidol. 13th Biennial winter workshop on Schizophrenia Research; 2006 February 4-10, Davos, Switzerland 2006.
67. Oren D, Marcus R, Kostic D, McQuade R, Iwamoto T, Archibald D. Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26, Atlanta, GA, USA 2005.
68. Oren D, Marcus R, Kostic D, McQuade R, Iwamoto T, Archibald D. Efficacy and Safety of Intramuscular Aripiprazole, Haloperidol or Placebo in Acutely Agitated Patients with Schizophrenia or Schizoaffective Disorder. Schizophrenia Bulletin 2005;31:499.
69. Yocca F, Marcus R, Oren D, Manos G, Carson W, Iwamoto T, Stock E. Intramuscular aripiprazole in acute schizophrenia: A pivotal phase-three study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, GA, USA 2005.
70. Wang 2005c {published data only} Wang G-P, Xie R, Pei G-X. A comparative study between aripiprazole and chlorpromazine in the treatment of schizophrenia. Shandong Archives of Psychiatry 2005;18(4):250-1.
71. Argo 2004 Argo TR, Carnahan RM, Perry PJ. Aripiprazole, a novel atypical antipsychotic drug. Pharmacotherapy 2004;24(2):212-28. [MEDLINE: 14998222].
72. Carson 2002a *Carson WH, Ingenito GG, McQuade RD, Stock EG, Iwamoto T. [Schizophrenia; safety/tolerability of aripiprazole]. XIIth World Congress of Psychiatry; Aug 24-29; Yokohama, Japan. 2002.
73. Carson 2004a Carson W, Marcus R, Jody D, Liston H, Pans M, Riera L, Iwamoto T. The effectiveness of switch to aripiprazole stratified by prior antipsychotic. American Psychiatric Association Annual Meeting; 2004 May 1-6, New York, NY, USA 2004.
74. Casey 2002 Casey D, Saha AR, Ali MW, Jody DN, Kujawa MJ, Stock EG, Ingenito GG. Switching to aripiprazole monotherapy. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S187.
75. Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG. Switching patients to aripiprazole from other antipsychotic agents : a multicenter randomised study. Psychopharmacology 2003;166(4):391- 9.
76. Casey DE, Saha AR, Ali MW, Jody D, Kujawa MJ, Stock EG, Ingenito GG. Switching to aripiprazole monotherapy. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennysylvania, USA. 2002.
77. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets ; medical review part 1. www.fda.gov/cder/foi/nda/2002/21-436_Abilify. htm 2002:1-50.
78. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets ; medical review part 2. www.fda.gov/cder/foi/nda/2002/21-436_Abilify. htm 2002:50-110.
79. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets ; medical review part 3. www.fda.gov/cder/foi/nda/2002/21-436_Abilify. htm 2002:111-75.
80. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets ; medical review part 4. www.fda.gov/cder/foi/nda/2002/21-436_Abilify. htm 2002:176-232.
81. Kujawa M, Saha AR, Ali MW, Jody DN, McQuade RD, Ingenito GG. Switching to aripiprazole monotherapy. Schizophrenia Research 2003;60:290.
82. Medori R, Gharbia N, Saha A, Ali M, Stock E, Ingenito G. Switching to aripiprazole monotherapy. Journal of the European College of Neuropsychopharmacology 2002;12(Suppl 3):S292.
83. Kelemen 2006 Kelemen O, Nagy O, Mattyassy A, Kiss I, Janka Z, Keri S. Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia ?. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S430.
84. Kim 2006 Kim JG, Cho DH, Lee SJ, Lee JK, Wang KS, Seo YI, Choi SJ, Joo MJ, Kim HD, Lee KH, Kwon YJ, Han KR. The comparison of efficacy between aripiprazole and haloperidol in treatment of chronic schizophrenia and schizoaffective disorder : results for 16-week clinical study. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S417.
85. Petrie 1997 *Petrie JL, Saha JR, McEvoy JP. Aripiprazole, a new typical antipsychotic: phase 2 clinical trial result. 10th European College of Neuropsychopharmacology Congres; Sep 13-17; Vienna, Austria. 1997.
86. Shim 2006 Shim JC, Kelly DL, Jung DU, Seo YS, Kim YH, Conley RR. Adjunctive treatment with a dopamine partial agonist, aripiprazole for antipsychotic-induced hyperprolactinaemia. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S405.
87. Swanson 2006a Swanson JW, Swartz MS, Van Dorn RA. Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada. 2006.
88. Wu 2005d Wu J-D, Li Y-D, Song Z-W. Effect of aripiprazole or haldol on intelligence and memory in the first-onset schizophrenia. Chinese Journal of Rehabilitation Theory and Practice 2006;12(1):64-5.
89. Xia 2005 Xia S-Y, Hua P, Nie Y-B. A treatment study of schizophrenia with aripiprazole and chlorpromazine. Practical Clinical Medicine 2005;6(10):33-4.
90. Currier 2006a, b Currier GW, Crandall D, Archibald D, Nyilas M, Kostic D, Pikalov A, Oren D. Intramuscular (im) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada. 2006.
91. Daniel 2006 *Daniel DG, Crandall D, Manos G, McQuade RD, Gutierrez-Esteinou R, Pikalov AA, Oren D. Transitioning from intramuscular (im) to oral aripiprazole in patients with schizophrenia. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada. 2006.
92. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
93. Andreasen 1985 Andreasen NC. Negative syndrome in schizophrenia: strategies for long-term management. Advances in Biochemical Psychopharmacology 1985;40:1-7.
94. Bland 1997 Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
95. Boissel 1999 Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problemof therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
96. Carpenter 1984 Heinrichs DW, Hanlon ET, Carpenter WT Jr. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10:388-96.
97. Carpenter 1994 Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
98. Christison 1991 Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic symptoms for schizophrenia. Schizophrenia Bulletin 1991;17:217-45.
99. Crow 1980 Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. British Journal of Psychiatry 1980;137:383-6.
100. Davis 1977 Davis JM, Casper R. Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs 1977;14:260-82.
101. Deeks 2000 Deeks J. Issues in the selection for meta-analysis of binary data. In: Abstracts of 8th International Cochrane Colloquim; 2000 Oct 25-28th; Cape Town, South Africa. 2000.
102. Divine 1992 Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behaviour. Journal of General Internal Medicine 1992;7:623-9.
103. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomised trials. Statistics in Medicine 2002;21:2971-80.
104. El-Sayeh 2006 El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2.Art. No.: CD004578. DOI:10.1002/14651858.CD004578.pub3.
105. FDA 2002a U.S. Federal Drug Administration CDER. Abilify (aripiprazole) tablets, medical review. www.fda.gov/cder/foi/nda/2002/21- 436_Abilify.htm 2002.
106. Gelder 2001 Gelder M, Lopez-Ibor jnr JJ, Andreason NC. Antipsychotic and anticholinergic drugs. New Oxford Textbook of Psychiatry. Vol. 2, Oxford: Oxford University Press, 2000:1314-16.
107. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
108. Guy 1976 Guy U. ECDEU assessment manual for psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976.
109. Hedlund 1980 Hedlund JL, Vieweg BW. The Brief Psychiatric Rating Scale (BPRS): a comprehensive review. Journal of Operational Psychiatry 1980;11:48-65.
110. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
111. Higgins 2005 Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Cochrane Database of Systematic Reviews 2005.
112. Jadad 1996 Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled clinical trials 1996;17:1-12.
113. Joy 2004 Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue 1.Art. No.: CD003082. DOI:10.1002/14651858.CD003082.pub2.
114. Jüni 2001 Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
115. Kane 1990 Kane JM. Treatment programme and long term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica 1990;358(suppl):151-7.
116. Kane 1993 Kane JM. Treatment programme and long term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica 1993;46:585-93.
117. Kay 1986 Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. North Tonawanda (NY): Multi-Health Systems, 1986.
118. Leucht 2005a Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry 2005;187:366-71.
119. Leucht 2005b Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
120. Marshall 2000 Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249-52.
121. Meltzer 1992 Meltzer HY. Treatment of the neuroleptic- nonresponsive schizophrenic patient. Schizophrenia Bulletin 1992;18:515-42.
122. Moher 2001 Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91.
123. Overall 1962 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
124. Rivas-Vasquez 2003 Rivas-Vasquez RA. Aripiprazole: A novel antipsychotic with dopamine stabilising properties. Professional Psychology: Research and Practice 2003;34(1):108-11.
125. Roland 1998 Roland M, Torgerson DJ. What are pragmatic trials?. BMJ 1998;316(7127):285.
126. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
127. Ukoumunne 1999 Ukoumunne OC, Gulliford MC. Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):3-92.